Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

April 2011

Clinical Trials, Cohort Studies, Pilot Studies

Coffee Consumption is Associated with Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C. Freedman ND, Curto TM, Lindsay KL, et al. Gastroenterology. 2011 Mar 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21376050

Insulin Resistance Is Independently Associated With Significant Hepatic Fibrosis in Asian Chronic Hepatitis C Genotype 2 Or 3 Patients. Patel K, Thompson A, Chuang W, et al. J Gastroenterol Hepatol. 2011 Mar 16. doi: 10.1111/j.1440-1746.2011.06722.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21410752

Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV infected children. Ruiz-Extremera A, Muñoz-Gámez J, Salmerón-Ruiz MA, et al. Hepatology. 2011 Mar 16. doi: 10.1002/hep.24298. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21413051

No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. Kronfol Z, Litman HJ, Back-Madruga C, et al. J Affect Disord. 2011 Mar;129(1-3):205-12.

http://www.ncbi.nlm.nih.gov/pubmed/20889211

Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trial. Ahmed F, Jacobson IM, Herrera JL, et al. J Clin Gastroenterol. 2011 Mar;45(3):286-92.

http://www.ncbi.nlm.nih.gov/pubmed/20930643

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Kamal SM, Ahmed A, Mahmoud S, et al. Liver Int. 2011 Mar;31(3):401-11. doi: 10.1111/j.1478-3231.2010.02435.x. Epub 2011 Jan 11.

http://www.ncbi.nlm.nih.gov/pubmed/21281434

Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. Itakura J, Asahina Y, Tamaki N, et al. Hepatol Res. 2011 Mar;41(3):217-24. doi: 10.1111/j.1872-034X.2010.00768.x.

http://www.ncbi.nlm.nih.gov/pubmed/21338453

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Arase Y, Suzuki F, Kobayashi M, et al. Hepatol Res. 2011 Mar 24. doi: 10.1111/j.1872-034X.2011.00798.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21435130

Chronic Hepatitis C Virus Infection is Associated with More Severe Asthma. Nakashima T, Yokoyama A, Ohnishi H, et al. Allergol Int. 2011 Mar 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21430435

Depression in patients with nonalcoholic Fatty liver disease and chronic viral hepatitis B and C. Weinstein AA, Kallman Price J, Stepanova M, et al. Psychosomatics. 2011 Mar-Apr;52(2):127-32.

http://www.ncbi.nlm.nih.gov/pubmed/21397104

Basic and Applied Science, Pre-Clinical Studies

The CD8+ T-Cell Response Promotes Evolution of Hepatitis C Virus Nonstructural Proteins. Ruhl M, Knuschke T, Schewior K, et al. Gastroenterology. 2011 Mar 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21376049

Strong CD8(+) T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Sistigu A, Bracci L, Valentini M, et al. Vaccine. 2011 Mar 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21382480

Association of Serum Cytokine Levels with Treatment Response to Pegylated Interferon and Ribavirin Therapy in Genotype 1 Chronic Hepatitis C Patients. Yoneda S, Umemura T, Katsuyama Y, et al. J Infect Dis. 2011 Mar 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21398397

Antiviral Stilbene 1,2-Diamines Prevent Initiation Of Hepatitis C Viral RNA Replication At The Outset of Infection. Gastaminza P, Pitram SM, Dreux M, et al. J Virol. 2011 Mar 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21430055

Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. Huang JF, Huang CF, Yu ML, et al. J Gastroenterol Hepatol. 2011 Mar;26(3):530-5. doi: 10.1111/j.1440-1746.2010.06438.x.

http://www.ncbi.nlm.nih.gov/pubmed/21332548

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H. Microbiol Immunol. 2011 Mar 4. doi: 10.1111/j.1348-0421.2011.00331.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21371092

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Moghaddam A, Melum E, Reinton N, et al. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.

http://www.ncbi.nlm.nih.gov/pubmed/21374656

HIV/HCV Coinfection

HCV RNA decline in the first 24h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Laufer N, Bolcic F, Rolón MJ, et al. Antiviral Res. 2011 Mar 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21376083

Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. Labarga P, Soriano V, Caruz A, et al. AIDS. 2011 Mar 27;25(6):761-766.

http://www.ncbi.nlm.nih.gov/pubmed/21378537

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. Trimoulet P, Belzunce C, Faure M, et al. HIV Med. 2011 Mar 16. doi: 10.1111/j.1468-1293.2011.00913.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21410862

Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Nguyen LH, Ko S, Wong SS, et al. Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21425314

Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection. Barrett L, Gallant M, Howley C, et al. J Viral Hepat. 2011 Mar;18(3):170-80. doi: 10.1111/j.1365-2893.2010.01293.x.

http://www.ncbi.nlm.nih.gov/pubmed/20497309

Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.

Rivero-Juárez A, Mira JA, Pérez-Camacho I, et al. J Antimicrob Chemother. 2011 Mar 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21415037

Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia. Gadalla SM, Preiss LR, Eyster ME, Goedert JJ. J Viral Hepat. 2011 Mar;18(3):161-9. doi: 10.1111/j.1365-2893.2010.01289.x.

http://www.ncbi.nlm.nih.gov/pubmed/20337924

A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. Butt AA, McGinnis K, Skanderson M, Justice AC. AIDS Res Hum Retroviruses. 2011 Mar 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21338329

Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. Neukam K, Nattermann J, Rallón N, et al. HIV Med. 2011 Mar 6. doi: 10.1111/j.1468-1293.2011.00912.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21375685

Complementary and Alternative Medicine

Diosgenin, a Plant-Derived Sapogenin, Exhibits Antiviral Activity in Vitro against Hepatitis C Virus. Wang YJ, Pan KL, Hsieh TC, Chang TY, Lin WH, Hsu JT. J Nat Prod. 2011 Mar 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21391660

Birch bark extract as therapy for chronic hepatitis C - A pilot study. Shikov AN, Djachuk GI, Sergeev DV, Pozharitskaya ON, Esaulenko EV, Kosman VM, Makarov VG. Phytomedicine. 2011 Mar 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21377854

Preliminary results of ozone therapy as a possible treatment for patients with chronic hepatitis C. Zaky S, Kamel SE, Hassan MS, et al. J Altern Complement Med. 2011 Mar;17(3):259-63.

http://www.ncbi.nlm.nih.gov/pubmed/21417811

Epidemiology, Diagnostics, and Miscellaneous Works

Non-Invasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C. Vergniol J, Foucher J, Terrebonne E, et al. Gastroenterology. 2011 Mar 1. [Epub ahead of print]

France.

http://www.ncbi.nlm.nih.gov/pubmed/21376047

Autotaxin as a novel serum marker of liver fibrosis. Nakagawa H, Ikeda H, Nakamura K, et al. Clin Chim Acta. 2011 Mar 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21419756

The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. Dibonaventura MD, Wagner JS, Yuan Y, et al. J Med Econ. 2011;14(2):253-61. Epub 2011 Mar 9.

http://www.ncbi.nlm.nih.gov/pubmed/21385147

Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort.

Arnold DT, Bentham LM, Jacob RP, Lilford RJ, Girling AJ. BMC Fam Pract. 2011 Mar 3;12:9.

http://www.ncbi.nlm.nih.gov/pubmed/21371303

Using mass media and the Internet as tools to diagnose hepatitis C infections in the general population. Zuure FR, Davidovich U, Coutinho RA, et al. Am J Prev Med. 2011 Mar;40(3):345-52.

http://www.ncbi.nlm.nih.gov/pubmed/21335268

Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C? Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 Mar 3. doi: 10.1111/j.1365-2702.2010.03494.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21371144

Population attributable fraction of infection-related cancers in Korea. Shin A, Park S, Shin HR, et al. Ann Oncol. 2011 Mar 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20974652

A Prospective Time Course Study on Serological Testing for Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus with Blood Samples Taken up to 48 Hours After Death. Edler C, Wulff B, Schroeder AS, et al. J Med Microbiol. 2011 Mar 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21436373

Liver Cancer

Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C. Lok AS, Everhart JE, Di Bisceglie AM, et al. Hepatology. 2011 Mar 3. doi: 10.1002/hep.24257. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21374690

Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis. Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Dig Dis Sci. 2011 Mar 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21374066

Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma. Kaibori M, Ishizaki M, Matsui K, Kitade H, Matsui Y, Kwon AH.

J Gastroenterol Hepatol. 2011 Mar;26(3):536-43. doi: 10.1111/j.1440-1746.2010.06439.x.

http://www.ncbi.nlm.nih.gov/pubmed/21332549

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. Nagaoki Y, Aikata H, Miyaki D, et al. J Gastroenterol. 2011 Mar 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21373851

Resection of a Transplantable Single-Nodule Hepatocellular Carcinoma in Child-Pugh Class A Cirrhosis: Factors Affecting Survival and Recurrence. Muscari F, Foppa B, Carrere N, Kamar N, Peron JM, Suc B. World J Surg. 2011 Mar 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21360309

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? Vezali E, Aghemo A, Lampertico P, Colombo M. Clin Res Hepatol Gastroenterol. 2011 Mar 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21435968

Tumor-related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. Kobayashi T, Itamoto T, Tashiro H, et al. J Hepatobiliary Pancreat Sci. 2011 Mar 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21445633